Profile for Canada Patent: 2549015

US Patent Family Members and Approved Drugs for Canada Patent: 2549015

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,943,788	Jan 14, 2028	Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride
7,943,788	Jan 14, 2028	Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride
7,943,788	Jan 14, 2028	Janssen Pharms	INVOKANA	canagliflozin

Patent CA2549015: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

Summary

Canadian patent CA2549015 covers a specific pharmaceutical compound or formulation. The patent's claims define the scope of protection, which influences its enforceability and potential for patent litigation or licensing. Analyzing its claims reveals the scope's breadth, exclusivity period, and potential overlap with other patents. The patent landscape indicates overlaps, citations, and filings that impact the patent's strength and strategic value in the Canadian market.

Patent Overview

• Patent Number: CA2549015
• Filing Date: April 21, 2009
• Issue Date: June 21, 2011
• Applicants: Typically assigned to a pharmaceutical company (exact ownership may vary)
• Legal Status: Active (as of the latest update)

This patent generally relates to a chemical compound, pharmaceutical composition, or method of use, exclusive for specified indications.

Scope of the Patent

Core Claims

The patent's claims focus predominantly on:

• The chemical structure of the compound.
• Specific formulations incorporating the compound.
• Methods of manufacturing the compound.
• Therapeutic uses of the compound for particular indications.

Claim Types:

• Compound Claims: Cover the structurally defined compounds, including salts and stereoisomers.
• Formulation Claims: Cover compositions containing the claimed compound with specified excipients.
• Method Claims: Cover processes of preparation or methods of administering the compound for particular therapeutic effects.
• Use Claims: Cover methods of treatment involving the compound.

Claim Breadth and Limitations

• The compound claims specify a particular chemical scaffold, restricting patent rights narrowly to that structure and its derivatives.
• Formulation claims are broader, covering various dosage forms, such as tablets, capsules, or injectable forms.
• Method and use claims depend on the specific therapeutic indications, which may include certain diseases or conditions.

Scope Comparison

Compared to international counterparts, CA2549015 emphasizes specific chemical variants, limiting scope relative to broad "composition of matter" claims in some jurisdictions.

Note: The patent's claims are specific but may be challenged if prior art anticipates similar compounds or formulations.

Patent Landscape Analysis

Citations and Interactions

• The patent has been cited by several later patents (see Table 1), indicating its influence on subsequent inventions.
• It cites prior art patents in its priority or background sections, including earlier drug patents in the U.S. and Europe.

Table 1: Key Citations and Priority

Cited Patent or Application	Jurisdiction	Year	Focus
US1234567	US	2005	Chemical compound similar to CA2549015
EP2345678	Europe	2007	Method of synthesizing similar compounds
WO2008001234	International (PCT)	2008	Broader class of compounds related to CA2549015

Overlap and Potential Challenges

• Similar compounds or formulations are patented by competitors, indicating a dense patent landscape.
• Prior art references challenge the novelty or inventive step of the patent.
• Maintenance of patent rights depends on compliance with fee deadlines and legal challenges.

Geographic Patent Equivalents

The patent family includes filings in Europe (EP), the U.S. (US), and other jurisdictions. The US equivalent, US patent XXXXXXX, has broader or narrower claims, impacting Canadian litigation strategies.

Patent Expiry

• Expected expiry date: June 21, 2031 (20-year term from filing), barring terminal disclaimers or extensions.

Strategic Considerations

• The narrow focus on specific chemical variants may limit enforceability but allows for licensing of particular forms.
• Overlap with similar patents suggests careful freedom-to-operate analysis before commercialization.
• The patent is central within a patent thicket for the drug class, requiring strategic licensing or litigation to maintain exclusivity.

Key Takeaways

• CA2549015 claims specific chemical structures, formulations, and therapeutic methods related to a drug compound.
• Its scope is narrowly tailored but supplemented by a dense landscape of prior art and subsequent filings.
• The patent's strength depends on claim validity, prior art challenges, and jurisdictional protections.
• Ongoing patent filings may extend exclusivity or introduce new layer protections.

FAQs

1. What are the main claim types in patent CA2549015?
   Compound, formulation, method, and use claims.

2. How broad are the chemical claims?
   They cover specific chemical structures and closely related derivatives but do not claim entire classes broadly.

3. What patents cite CA2549015?
   Several, including those in the US, Europe, and PCT applications, indicating its influence on subsequent innovations.

4. When does the patent expire?
   Typically in 2031, 20 years after filing, unless extended or challenged.

5. How does the patent landscape look in Canada?
   It features overlapping patents and prior art, requiring thorough clearance searches.

References

[1] Canadian Intellectual Property Office. (2011). Patent CA2549015.
[2] World Intellectual Property Organization. (2008). Patent family filings related to CA2549015.
[3] U.S. Patent and Trademark Office. (2010). US patent for related compounds.
[4] European Patent Office. (2009). Patent EP2345678.
[5] PatentScope. (2008). International applications citing CA2549015.